[go: up one dir, main page]

WO2022031783A3 - Polypeptides adaptateurs et méthodes d'utilisation de ces derniers - Google Patents

Polypeptides adaptateurs et méthodes d'utilisation de ces derniers Download PDF

Info

Publication number
WO2022031783A3
WO2022031783A3 PCT/US2021/044449 US2021044449W WO2022031783A3 WO 2022031783 A3 WO2022031783 A3 WO 2022031783A3 US 2021044449 W US2021044449 W US 2021044449W WO 2022031783 A3 WO2022031783 A3 WO 2022031783A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
same
adapter polypeptides
polypeptides
adapter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/044449
Other languages
English (en)
Other versions
WO2022031783A2 (fr
Inventor
Ly James Lee
Chi-Ling CHIANG
Yifan MA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spot Biosystems Ltd
Ohio State Innovation Foundation
Original Assignee
Spot Biosystems Ltd
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spot Biosystems Ltd, Ohio State Innovation Foundation filed Critical Spot Biosystems Ltd
Priority to CN202180068299.2A priority Critical patent/CN116782932A/zh
Priority to EP21853397.4A priority patent/EP4192503A2/fr
Priority to JP2023507972A priority patent/JP2023536665A/ja
Priority to CA3190722A priority patent/CA3190722A1/fr
Priority to US18/018,519 priority patent/US20240299529A1/en
Publication of WO2022031783A2 publication Critical patent/WO2022031783A2/fr
Publication of WO2022031783A3 publication Critical patent/WO2022031783A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions de vésicules extracellulaires, ainsi que des méthodes et des systèmes de production des vésicules extracellulaires. L'invention concerne également des méthodes d'utilisation des vésicules extracellulaires.
PCT/US2021/044449 2020-08-05 2021-08-04 Polypeptides adaptateurs et méthodes d'utilisation de ces derniers Ceased WO2022031783A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202180068299.2A CN116782932A (zh) 2020-08-05 2021-08-04 衔接多肽及其使用方法
EP21853397.4A EP4192503A2 (fr) 2020-08-05 2021-08-04 Polypeptides adaptateurs et méthodes d'utilisation de ces derniers
JP2023507972A JP2023536665A (ja) 2020-08-05 2021-08-04 アダプターポリペプチドおよびその使用方法
CA3190722A CA3190722A1 (fr) 2020-08-05 2021-08-04 Polypeptides adaptateurs et methodes d'utilisation de ces derniers
US18/018,519 US20240299529A1 (en) 2020-08-05 2021-08-04 Adapter polypeptides and methods of using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061749P 2020-08-05 2020-08-05
US63/061,749 2020-08-05

Publications (2)

Publication Number Publication Date
WO2022031783A2 WO2022031783A2 (fr) 2022-02-10
WO2022031783A3 true WO2022031783A3 (fr) 2022-04-07

Family

ID=80117691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/044449 Ceased WO2022031783A2 (fr) 2020-08-05 2021-08-04 Polypeptides adaptateurs et méthodes d'utilisation de ces derniers

Country Status (6)

Country Link
US (1) US20240299529A1 (fr)
EP (1) EP4192503A2 (fr)
JP (1) JP2023536665A (fr)
CN (1) CN116782932A (fr)
CA (1) CA3190722A1 (fr)
WO (1) WO2022031783A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116171163A (zh) * 2019-08-06 2023-05-26 俄亥俄州国家创新基金会 治疗性细胞外囊泡

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598350B2 (en) * 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
US20150239956A1 (en) * 2012-06-27 2015-08-27 Asahi Kasei Medical Co., Ltd. High-affinity antibody and method for manufacturing the same
WO2018015535A1 (fr) * 2016-07-21 2018-01-25 Evox Therapeutics Ltd Vésicule extracellulaire comprenant une protéine de fusion ayant une capacité de liaison de fc
US20180327494A1 (en) * 2015-07-31 2018-11-15 Suzhou Alphamab Co., Ltd. Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)
US10398680B2 (en) * 2012-09-10 2019-09-03 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3057662A4 (fr) * 2013-10-17 2017-03-29 Children's Hospital Los Angeles Thérapie par exosomes dépendant d'un anticorps
JP2022513312A (ja) * 2018-09-21 2022-02-07 シティー・ユニバーシティー・オブ・ホンコン 表面修飾細胞外小胞
CN109082404B (zh) * 2018-10-22 2020-12-25 厦门艾赛生物科技有限公司 一种靶向性外泌体的制备方法及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598350B2 (en) * 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
US20150239956A1 (en) * 2012-06-27 2015-08-27 Asahi Kasei Medical Co., Ltd. High-affinity antibody and method for manufacturing the same
US10398680B2 (en) * 2012-09-10 2019-09-03 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US20180327494A1 (en) * 2015-07-31 2018-11-15 Suzhou Alphamab Co., Ltd. Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)
WO2018015535A1 (fr) * 2016-07-21 2018-01-25 Evox Therapeutics Ltd Vésicule extracellulaire comprenant une protéine de fusion ayant une capacité de liaison de fc

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL.: "3D nanochannel electroporation for high-throughput cell transfection with high uniformity and dosage control", NANOSCALE, vol. 8, no. 1, 1 January 2016 (2016-01-01), United Kingdom , pages 243 - 252, XP055790463, ISSN: 2040-3364, DOI: 10.1039/C5NR03187G *

Also Published As

Publication number Publication date
US20240299529A1 (en) 2024-09-12
CN116782932A (zh) 2023-09-19
JP2023536665A (ja) 2023-08-28
EP4192503A2 (fr) 2023-06-14
CA3190722A1 (fr) 2022-02-10
WO2022031783A2 (fr) 2022-02-10

Similar Documents

Publication Publication Date Title
WO2020172492A3 (fr) Préparations de membrane bactérienne
WO2020008377A3 (fr) Peptides ioniques à auto-assemblage
WO2020172420A3 (fr) Formulation concentrée nettoyante anhydre stable et son procédé de fabrication
WO2019183359A8 (fr) Procédés et compositions pour l'authentification moléculaire
EP4112124A4 (fr) Vésicule extracellulaire de présentation d'antigène, composition contenant celle-ci, et procédé destiné à la fabrication de celles-ci
WO2020106338A3 (fr) Hydrogels zwittérioniques à double réseau
MX2023007114A (es) Películas solubles en agua, artículos de dosis unitaria solubles en agua y métodos de fabricación y uso de los mismos.
WO2019232025A8 (fr) Production technologique de microbes pour produire des isoprénoïdes
AU2018325363A1 (en) Improved BLue Aleurone and other segregation systems
TWD201836S (zh) 通訊耳機之部分
WO2019108871A8 (fr) Revêtements résistant aux salissures biologiques et leurs procédés de fabrication et d'utilisation
WO2023049790A3 (fr) Agents de dégradation de mdm2 et leurs utilisations
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
EP3946269A4 (fr) Procédés de fabrication de vésicules ciblées, et compositions ainsi fabriquées
WO2019136318A3 (fr) Compositions et procédés pour produire des mégacaryocytes
WO2023081762A3 (fr) Recombinases à sérine
WO2023009529A3 (fr) Nouveaux polypeptides et leurs utilisations
MX2023007113A (es) Peliculas solubles en agua, articulos de dosis unitaria solubles en agua y metodos de fabricacion y uso de los mismos.
WO2022235755A3 (fr) Polypeptides par fusion
WO2022204129A8 (fr) Récepteur chimérique de co-stimulation de cd38 et ses utilisations
WO2022031783A3 (fr) Polypeptides adaptateurs et méthodes d'utilisation de ces derniers
WO2020237122A3 (fr) Systèmes de nettoyage pour appareils de fabrication additive et leurs procédés d'utilisation
MX2023014628A (es) Vectores de expresion, vectores libres de secuencias bacterianas y metodos para fabricar y usar los mismos.
WO2020154405A3 (fr) Anticorps de type immunoglobuline a et leurs procédés de production et méthodes d'utilisation
WO2022031862A3 (fr) Composés hétéroaryle et hétérocyclyle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21853397

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2023507972

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3190722

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021853397

Country of ref document: EP

Effective date: 20230306

WWE Wipo information: entry into national phase

Ref document number: 202180068299.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21853397

Country of ref document: EP

Kind code of ref document: A2